Further analysis of the DN B cell subsets showed that the percentage of CD38− DN B cells was significantly higher in patients with SLE and RA than in the control group (median: 2.4% vs. 0.9%, p = 0.004; median: 2.0% vs. 0.9%, p = 0.020, respectively). This evidence concerns the gene CD38 and rheumatoid arthritis.